search
Back to results

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

Primary Purpose

Atopic Dermatitis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cetaphil Restoraderm
Standard of Care
Sponsored by
Oregon Health and Science University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Atopic Dermatitis focused on measuring atopic dermatitis, skin care

Eligibility Criteria

1 Day - 3 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Infants up to three weeks of age born to mothers aged 18-45 years will be recruited for this study.
  • Infants must have a family history of asthma, eczema, or hayfever in at least one first-degree relative and be in otherwise good overall health.

Exclusion Criteria:

  • Preterm birth defined as birth prior to 37 weeks gestation
  • Major congenital anomaly
  • Hydrops fetalis
  • Significant dermatitis at birth not including seborrheic dermatitis on the scalp ("cradle cap")
  • Any immunodeficiency disorder
  • Any severe genetic skin disorder
  • Any other serious condition that would make the use of emollients inadvisable
  • Any other major medical problems that the investigator deems may increase the risk of adverse events with the intervention or in whom assessing the outcomes may be masked by the underlying problem or practically very difficult to assess

Sites / Locations

  • Oregon Health & Science University Center for Health & Healing

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard of Care

Cetaphil Restoraderm

Arm Description

Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.

Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.

Outcomes

Primary Outcome Measures

Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months
Percentage of cumulative Atopic Dermatitis diagnosed by a blinded investigator at 12 months

Secondary Outcome Measures

Percentage of High Emollient Use
Patient-reported adherence to the emollient regimen in the intervention group and the treatment group. High emollient use was defined as applying the intervention or control emollient five or more days per week.
Age at Onset of Eczema
Age of subject at onset of eczema
Filaggrin Mutation Status
Filaggrin mutation status result
Transepidermal Water Loss (TEWL)
Transepidermal water loss (TEWL) to measure skin barrier function
Skin Hydration (Skin Electrical Capacitance)
Determination of stratum corneum hydration from the dorsal forearm
Skin pH
Skin pH, as measured using a pH probe

Full Information

First Posted
June 15, 2011
Last Updated
January 30, 2020
Sponsor
Oregon Health and Science University
Collaborators
Galderma R&D
search

1. Study Identification

Unique Protocol Identification Number
NCT01375205
Brief Title
Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
Official Title
A Randomized Pilot Trial Comparing Cetaphil® Restoraderm® System and Standard Skin Care in Infants at Risk for Atopic Dermatitis
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
June 2011 (Actual)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
Collaborators
Galderma R&D

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this study is to determine what effect Cetaphil® Restoraderm® system has on babies' skin versus Johnson & Johnson baby lotion and skin cleanser.
Detailed Description
Subjects will randomly be divided into a group using Cetaphil® Restoraderm® system or a group using Johnson & Johnson baby lotion and skin cleanser . At 3, 6, and 12 months non-invasive measurements of barrier function will be used to test the babies' skin. The procedures are as follows: Transepidermal loss (TEWL - measures the water loss from the skin) Skin electrical capacitance (measures how much water stays in the top layer of skin) Skin pH (measures level of pH) Skin microbiome analysis (skin swabs to check genetic code of skin bacteria) Lipidomic and natural moisturizing factor analysis (measures lipids (oils) in the top layer of skin) Both groups will be reminded to follow the instructions about general good skin care of infants. Subjects will be asked if they agree to provide a saliva sample. If yes, a saliva sample will be collected from the inside of the infant's cheek at the 6 month visit and will be shipped to the laboratory of Dr. Irwin McLean at the University of Dundee, where it will be tested for gene defects in the skin barrier that might trigger the development of eczema. Defects in the gene called filaggrin have been shown to increase the risk of developing eczema. The samples will be identified by a code to protect your infant's identity. The saliva samples will be stored only for this study, and then the sample will be destroyed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis
Keywords
atopic dermatitis, skin care

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
Arm Title
Cetaphil Restoraderm
Arm Type
Experimental
Arm Description
Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Intervention Type
Other
Intervention Name(s)
Cetaphil Restoraderm
Intervention Description
Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Intervention Type
Other
Intervention Name(s)
Standard of Care
Other Intervention Name(s)
Johnson&Johnson
Intervention Description
Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
Primary Outcome Measure Information:
Title
Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months
Description
Percentage of cumulative Atopic Dermatitis diagnosed by a blinded investigator at 12 months
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Percentage of High Emollient Use
Description
Patient-reported adherence to the emollient regimen in the intervention group and the treatment group. High emollient use was defined as applying the intervention or control emollient five or more days per week.
Time Frame
2, 6, 12, 18, and 24 months
Title
Age at Onset of Eczema
Description
Age of subject at onset of eczema
Time Frame
Baseline through Month 24 Follow-up
Title
Filaggrin Mutation Status
Description
Filaggrin mutation status result
Time Frame
6 month visit
Title
Transepidermal Water Loss (TEWL)
Description
Transepidermal water loss (TEWL) to measure skin barrier function
Time Frame
2 month, 6 month, and 12 month visits
Title
Skin Hydration (Skin Electrical Capacitance)
Description
Determination of stratum corneum hydration from the dorsal forearm
Time Frame
2 month, 6 month, and 12 month visits
Title
Skin pH
Description
Skin pH, as measured using a pH probe
Time Frame
2 month, 6 month, and 12 month visits

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
3 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infants up to three weeks of age born to mothers aged 18-45 years will be recruited for this study. Infants must have a family history of asthma, eczema, or hayfever in at least one first-degree relative and be in otherwise good overall health. Exclusion Criteria: Preterm birth defined as birth prior to 37 weeks gestation Major congenital anomaly Hydrops fetalis Significant dermatitis at birth not including seborrheic dermatitis on the scalp ("cradle cap") Any immunodeficiency disorder Any severe genetic skin disorder Any other serious condition that would make the use of emollients inadvisable Any other major medical problems that the investigator deems may increase the risk of adverse events with the intervention or in whom assessing the outcomes may be masked by the underlying problem or practically very difficult to assess
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Simpson, MD, MCR
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oregon Health & Science University Center for Health & Healing
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

We'll reach out to this number within 24 hrs